Han Yi-Peng, Ma Chen-Kai, Wang Shen-Qi, Enomoto Atsushi, Zhao Yang, Takahashi Masahide, Ma Jie
Department of Pediatric Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China.
J Neurooncol. 2014 Sep;119(2):343-51. doi: 10.1007/s11060-014-1484-4. Epub 2014 May 31.
Osteopontin (OPN) is a protein linked to tumor growth, progression and metastasis of cancers. However, its role in the progression of central nervous system (CNS) embryonal tumors such as atypical teratoid/rhabdoid tumor (AT/RT), medulloblastoma (MB) and primitive neuroepithelial tumors (PNET) remains elusive. In this study, we investigated the value of OPN staining in differential diagnosis of AT/RT from MB and PNET, and assessed the correlation between OPN expression and patients' prognosis. This retrospective study was conducted on tissue sections obtained from children cases with CNS embryonal tumors treated in Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine from 2006 to 2012 by immunohistochemistry (IHC). 49 cases were collected (11 AT/RTs, 25 MBs, and 13 PNETs), with a median follow-up time of 28.9 months. OPN expression in AT/RT was significantly higher than MB and PNET with the positive rates of 100, 32, and 23 %, respectively (P < 0.01). The specificity and sensitivity of OPN staining in diagnosing AT/RT are 97.4 and 90.9 %, respectively, as judged by strong OPN IHC staining level (+++). Patients who had positive OPN staining have increased risks of poorer median overall survival (hazard risk 5.54, 95 % CI 1.87-16.38) and tumor progression (hazard risk 14.47, 95 % CI 4.47-46.85). OPN is a valuable biomarker to aid in the differential diagnosis between AT/RT and MB/PNET. Moreover, OPN is a potential novel prognostic marker for CNS embryonal tumors.
骨桥蛋白（OPN）是一种与肿瘤生长、进展及转移相关的蛋白质。然而，其在中枢神经系统（CNS）胚胎性肿瘤（如非典型畸胎样/横纹肌样瘤（AT/RT）、髓母细胞瘤（MB）和原始神经上皮肿瘤（PNET））进展中的作用仍不清楚。在本研究中，我们调查了OPN染色在AT/RT与MB及PNET鉴别诊断中的价值，并评估了OPN表达与患者预后的相关性。本回顾性研究通过免疫组织化学（IHC）对2006年至2012年在上海交通大学医学院附属新华医院接受治疗的儿童CNS胚胎性肿瘤病例的组织切片进行分析。共收集49例病例（11例AT/RT、25例MB和13例PNET），中位随访时间为28.9个月。AT/RT中OPN的表达显著高于MB和PNET，阳性率分别为100%、32%和23%（P<0.01）。根据OPN IHC强染色水平（+++）判断，OPN染色诊断AT/RT的特异性和敏感性分别为97.4%和90.9%。OPN染色阳性的患者中位总生存期较差（风险比5.54，95%可信区间1.87 - 16.38）和肿瘤进展（风险比14.47，95%可信区间4.47 - 46.85）的风险增加。OPN是有助于AT/RT与MB/PNET鉴别诊断的有价值生物标志物。此外，OPN是CNS胚胎性肿瘤潜在的新型预后标志物。
